ES2139017T3 - Compuestos que inhiben la replicacion del vih. - Google Patents

Compuestos que inhiben la replicacion del vih.

Info

Publication number
ES2139017T3
ES2139017T3 ES93917272T ES93917272T ES2139017T3 ES 2139017 T3 ES2139017 T3 ES 2139017T3 ES 93917272 T ES93917272 T ES 93917272T ES 93917272 T ES93917272 T ES 93917272T ES 2139017 T3 ES2139017 T3 ES 2139017T3
Authority
ES
Spain
Prior art keywords
hiv
refers
hiv replication
inhibiting hiv
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917272T
Other languages
English (en)
Inventor
Carl T Wild
Thomas J Matthews
Dani P Bolognesi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Application granted granted Critical
Publication of ES2139017T3 publication Critical patent/ES2139017T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A FRAGMENTOS DE PROTEINAS DEL VIRUS DE INMUNODEFICIENCIA HUMANA (VIH) QUE POSEEN UNA ACTIVIDAD ANTIVIRAL Y EN PARTICULAR SE REFIERE A PEPTIDOS DEL VIH DERIVADOS DE LA GLICOPROTEINA DE LA TRANSMEMBRANA DEL VIH (GP41) QUE INHIBE LA FUSION CELULA-CELULA INDUCIDA POR EL VIH. LA INVENCION TAMBIEN SE REFIERE A LOS METODOS PARA INHIBIR LA INFECCION DE VIRUS CON TUNICA Y A METODOS QUE MODULAN LOS PROCESOS BIOQUIMICOS EN LOS QUE INTERVIENEN INTERACCIONES DE PEPTIDOS RIZADOS EN ESPIRAL.
ES93917272T 1992-07-20 1993-07-19 Compuestos que inhiben la replicacion del vih. Expired - Lifetime ES2139017T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91654092A 1992-07-20 1992-07-20
US92753292A 1992-08-07 1992-08-07

Publications (1)

Publication Number Publication Date
ES2139017T3 true ES2139017T3 (es) 2000-02-01

Family

ID=27129697

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917272T Expired - Lifetime ES2139017T3 (es) 1992-07-20 1993-07-19 Compuestos que inhiben la replicacion del vih.

Country Status (11)

Country Link
US (3) US5656480A (es)
EP (1) EP0652895B1 (es)
JP (1) JP4010560B2 (es)
KR (1) KR100358209B1 (es)
AT (1) ATE183515T1 (es)
AU (1) AU688733B2 (es)
CA (1) CA2140663C (es)
DE (1) DE69326069T2 (es)
ES (1) ES2139017T3 (es)
NZ (1) NZ254640A (es)
WO (1) WO1994002505A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69326069T2 (de) * 1992-07-20 2000-03-23 Duke University, Durham Zusammensetzungen die die hiv replikation inhibieren
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
WO1996040191A1 (en) * 1995-06-07 1996-12-19 Trimeris, Inc. The treatment of hiv and other viral infections using combinatory therapy
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
AU6649698A (en) * 1997-01-28 1998-08-18 Regents Of The University Of California, The Peptide probes to coil proteins and methods for making the same
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
GB9801070D0 (en) * 1998-01-19 1998-03-18 Andaris Ltd HIV inhibition
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
KR20010099605A (ko) * 1998-07-30 2001-11-09 존 프랫 Ｈｉｖ 막융합 억제제
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
CA2359892A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
EP1264840B1 (en) * 1999-05-17 2009-09-23 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US6469136B1 (en) * 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
US6541020B1 (en) * 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US7053179B2 (en) 1999-12-16 2006-05-30 Whitehead Institute For Biomedical Research Five-Helix protein
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
AU3334001A (en) 2000-02-10 2001-08-20 Panacos Pharmaceuticals Inc Assay for detection of viral fusion inhibitors
US6623741B1 (en) 2000-02-29 2003-09-23 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
US6528308B1 (en) * 2000-03-16 2003-03-04 Duke University Suppressor of HIV replication and transcription
NZ521977A (en) * 2000-03-17 2004-05-28 Panacos Pharmaceuticals Inc A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of HIV envelope proteins
PT1479691E (pt) * 2001-05-31 2007-02-28 John Erickson Inibidores de péptido de fusão de longa duração para a infecção por hiv
EP1752469B1 (en) * 2001-05-31 2008-10-29 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors for HIV infection
CA2450548C (en) 2001-06-15 2012-05-01 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
US20030125515A1 (en) * 2001-07-11 2003-07-03 Genfa Zhou End-locked five-helix protein
CN1100564C (zh) * 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
WO2003048187A2 (en) * 2001-11-29 2003-06-12 Mymetics, Corp. Peptides and use thereof in therapeutic agents against hiv infection
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
US7556813B2 (en) * 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
WO2004035808A2 (en) * 2002-10-16 2004-04-29 Panacos Pharmaceuticals, Inc. Method for detecting viral inactivating agents
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
EP1578461A4 (en) * 2002-12-18 2008-09-03 Univ Maryland Biotech Inst VACCINES AGAINST HIV TAT PROTEIN FOR GENERATING NEUTRALIZING ANTIBODIES
US20070178561A1 (en) * 2003-05-08 2007-08-02 Anderson Porter W Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein
AU2003265420A1 (en) * 2003-08-14 2005-03-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Polypeptide multimers having antiviral activity
KR20050024730A (ko) * 2003-09-01 2005-03-11 코바이오텍 (주) Ｔ―２０ 펩타이드 코딩 유전자를 포함하는 재조합대장균의 고농도 세포 배양 방법 및 이로부터 생산된ｔ―２０ 펩타이드의 분리 및 정제 방법
US7744897B2 (en) 2003-12-23 2010-06-29 Dillon Susan B Human immunodeficiency virus gp41 mimetibody polypeptides
WO2005063791A2 (en) * 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Process for peptide synthesis using a reduced amount of deprotection agent
EP1701971A2 (en) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Peptide synthesis using decanting filter
WO2005063792A2 (en) * 2003-12-31 2005-07-14 F. Hoffmann-La Roche Ag Methods for recovering cleaved peptide from a support
EP1701976A2 (en) * 2003-12-31 2006-09-20 F.Hoffmann-La Roche Ag Peptide synthesis and deprotection with co-solvent
ES2315729T3 (es) * 2003-12-31 2009-04-01 F. Hoffmann-La Roche Ag Procedimiento y sistemas para la recuperacion de peptidos.
BRPI0418304A (pt) * 2004-01-07 2007-05-02 Trimeris Inc peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv
WO2005108418A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
JP5069558B2 (ja) 2004-06-01 2012-11-07 メルク・シャープ・エンド・ドーム・コーポレイション ＨＩＶｇｐ４１融合中間物質の安定したペプチド模倣薬
US7744887B2 (en) * 2004-06-01 2010-06-29 Merck & Co., Inc. Human antibodies interacting with HIV gp41
WO2006069729A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Synthesis of peptide t-1249 using peptide intermediate fragments
EP1833843B1 (en) * 2004-12-30 2009-10-14 F. Hoffmann-La Roche Ag Synthesis of peptide t-20 using peptide intermediate fragments
WO2006069697A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Colorimetrically assessing peptide characteristics
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
EP2279756A2 (en) * 2005-04-05 2011-02-02 Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A. Method for shielding functional sites or epitopes on proteins
CN101415723B (zh) 2006-02-02 2014-06-25 特里梅里斯公司 具有改良生物学特性的hiv融合抑制肽
JP2008005838A (ja) * 2006-05-31 2008-01-17 Wataru Sakamoto 新規ペルオキシダーゼ検出用試薬組成物及びこれを用いた炎症疾患等の判定法および抗酸化活性測定法
JP2010500984A (ja) 2006-08-17 2010-01-14 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ５に対する抗体と抗膜融合ペプチドとの抱合体
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
JP5492563B2 (ja) 2006-12-12 2014-05-14 バイオレクシス ファーマシューティカル コーポレーション トランスフェリン融合タンパク質ライブラリー
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
WO2008124013A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
EP2147016A2 (en) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
JP2010540528A (ja) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド 治療的抗ウイルス性ペプチドの新規合成方法
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
ES2535704T3 (es) 2010-09-14 2015-05-14 F. Hoffmann-La Roche Ag Polipéptido de fusión serpina-dedo
WO2013150532A1 (en) 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
WO1987006005A1 (en) * 1986-03-24 1987-10-08 Ortho Pharmaceutical Corporation Synthetic htlv-iii peptides, compositions and uses thereof
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
EP0323157A3 (en) * 1987-12-24 1990-07-25 The University Of Melbourne Antiviral compounds and methods
EP0323425B1 (en) * 1987-12-28 1995-09-06 Yamaha Corporation An ivory-like key material and a method for producing the same
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides
US5444044A (en) * 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
DE69326069T2 (de) * 1992-07-20 2000-03-23 Duke University, Durham Zusammensetzungen die die hiv replikation inhibieren
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same

Also Published As

Publication number Publication date
DE69326069D1 (de) 1999-09-23
KR100358209B1 (ko) 2003-01-24
US6573078B1 (en) 2003-06-03
WO1994002505A1 (en) 1994-02-03
NZ254640A (en) 1997-04-24
JP4010560B2 (ja) 2007-11-21
CA2140663A1 (en) 1994-02-03
EP0652895B1 (en) 1999-08-18
EP0652895A1 (en) 1995-05-17
AU4683793A (en) 1994-02-14
US5656480A (en) 1997-08-12
CA2140663C (en) 2004-01-27
EP0652895A4 (en) 1997-02-05
AU688733B2 (en) 1998-03-19
US20030181382A1 (en) 2003-09-25
KR950702575A (ko) 1995-07-29
DE69326069T2 (de) 2000-03-23
ATE183515T1 (de) 1999-09-15
JPH08500342A (ja) 1996-01-16

Similar Documents

Publication Publication Date Title
ES2139017T3 (es) Compuestos que inhiben la replicacion del vih.
ES2053413T3 (es) Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
MX9304837A (es) Peptidos capaces de inhibir la actividad de proteasa vih, su preparacion y su uso terapeutico.
MX9203379A (es) Proteinas producidas por los linfocitos humanos, secuencia de adn que codifica para estas proteinas y composiciones farmaceuticas que las contienen.
ES2002490A6 (es) Un metodo de preparar un virus recombinante
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
ES2067457T3 (es) Celula de origen animal con una proteina antigenica introducida en ella.
PE43298A1 (es) Genes sinteticos de vih
CL2009002139A1 (es) Peptido sintetico que comprende la secuencia sec id no:6 y sec id no:7 de la proteina gp41 del virus vih con actividad antiretroviral.
ES2057191T5 (es) Metodo de produccion para una composicion que contiene proteinas.
ES2138086T3 (es) Constructo de peptido sintetico compuesto que provoca anticuerpos neutralizantes y linfocitos t citotoxicos contra hiv.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
ES2134197T3 (es) Vacunas contra el virus del herpes simplex vp16.
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
ES2127294T3 (es) Vacunas del virus de la inmunodeficiencia anti-felino (fiv).
ES2115622T3 (es) Clones moleculares de hiv-1 y usos de los mismos.
ES2138603T3 (es) Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
DE68925660D1 (de) Peptidfragmente von HIV
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
ES2119747T3 (es) Metodo para la preparacion y purificacion de una mezcla de glicosfingolipidos libre de contaminacion por virus no convencionales.
ES2118242T3 (es) Vacunas anti virus de la inmunodeficiencia felina (fiv).

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 652895

Country of ref document: ES